Sonoma Pharmaceuticals (NASDAQ: SNOA) and Dynavax Technologies (NASDAQ:DVAX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.
Risk and Volatility
Sonoma Pharmaceuticals has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Dynavax Technologies has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.
Earnings and Valuation
This table compares Sonoma Pharmaceuticals and Dynavax Technologies’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sonoma Pharmaceuticals||$12.82 million||1.42||$9.27 million||($2.79)||-1.38|
|Dynavax Technologies||$330,000.00||3,121.38||-$95.15 million||($1.84)||-9.08|
Sonoma Pharmaceuticals has higher revenue and earnings than Dynavax Technologies. Dynavax Technologies is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent recommendations and price targets for Sonoma Pharmaceuticals and Dynavax Technologies, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sonoma Pharmaceuticals currently has a consensus price target of $8.50, suggesting a potential upside of 120.78%. Dynavax Technologies has a consensus price target of $27.40, suggesting a potential upside of 64.07%. Given Sonoma Pharmaceuticals’ higher probable upside, equities research analysts clearly believe Sonoma Pharmaceuticals is more favorable than Dynavax Technologies.
Institutional & Insider Ownership
13.2% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 71.2% of Dynavax Technologies shares are held by institutional investors. 13.3% of Sonoma Pharmaceuticals shares are held by insiders. Comparatively, 2.9% of Dynavax Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares Sonoma Pharmaceuticals and Dynavax Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Dynavax Technologies beats Sonoma Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc., formerly Oculus Innovative Sciences, Inc., is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid. Microcyn is a small-molecule oxychlorine compound with antimicrobial and anti-inflammatory properties that, in clinical settings, reduces itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue. Lipogrid Technology contains selected lipids and a lipid precursor designed to penetrate the bilayers of the skin by blending with the natural lipid building blocks. Its products serve over five million patients across the globe by reducing infections, itch, pain, scarring and inflammatory responses. Its products are sold throughout the United States and internationally.
About Dynavax Technologies
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.